Entrepreneurship in Biotech

University spin-offs play an important role in the innovation landscape, often transforming cutting-edge research into impactful industry applications.

In our 9th Innoscape Talk, we explore the success story of T3 Pharmaceuticals with CEO and founder Simon Ittig. The company, with its origins at the Biozentrum of the University of Basel, has been acquired by Boehringer Ingelheim in a significant deal, underscoring the value of their approach and the potential of their technology.

Despite significant advances of classical therapies, there remains a high need for novel and innovative medicines to treat cancer. T3 Pharmaceuticals is dedicated to filling this gap by developing highly specific and efficient treatments using live bacteria.

Simon outlines T3 Pharmaceuticals’ journey from its roots in academic research to becoming a leader in bacterial cancer therapy. He talks about initial funding hurdles, ensuring the growth of the company, and the optimal timing for forging key partnerships. He also offers practical advice for aspiring Swiss entrepreneurs and discusses the pivotal role of the Basel life science cluster in fostering innovation, highlighting the remarkable transition of scientific research into a thriving business.